Is Circulating Tumor DNA Ready for Clinical Use in Large B-cell Lymphoma?

Circulating tumor DNA can detect measurable residual disease after frontline therapy in large B-cell lymphoma, addressing molecular-only relapse that PET misses.

• Why it matters: PET-based response criteria risk misclassifying patients who have residual molecular disease without detectable lesions, complicating decisions after treatment.
• What they did: The work reviews clinical implementation of circulating tumor DNA–based MRD as an adjunct to existing response assessment, outlining what data are needed for broader use.
• The result: Using ctDNA MRD after therapy may improve risk stratification and support complex clinical decision-making, but additional evidence is required to realize its full potential.

AI summary of the abstract · may contain errors · not medical advice · read the paper.